STAMFORD, Conn.--(BUSINESS WIRE)--Sema4, a patient-centered health intelligence company, today announced the appointment of William K. Oh, M.D., to the newly established senior leadership position of Chief Medical Science Officer. Dr. Oh, who was previously Chair of Sema4’s Scientific Advisory Board for Oncology, is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers at Harvard and Mount Sinai.
“We are privileged to have a world-renowned oncologist of William’s stature join the Sema4 team. His deep clinical expertise will help us further establish our leadership in delivering data-driven precision oncology solutions that support improved patient outcomes,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “As part of our senior leadership team, William will play a critical role in the development of our strategy, scientific collaborations, clinical development programs, and the adoption of our advanced health intelligence offerings in oncology and also across a broad spectrum of human diseases.”
Dr. Oh was most recently Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at the Icahn School of Medicine at Mount Sinai in New York. He was also the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at Mount Sinai. In addition to his roles as a widely respected clinician, researcher, and principal investigator of multiple clinical trials, he developed large clinical databases and specimen biorepositories for genitourinary cancers at Harvard’s Dana-Farber Cancer Institute, and Mount Sinai. Dr. Oh has authored more than 300 articles, reviews, and book chapters related to prostate, renal, bladder, and testicular cancers. He is a graduate of Yale College and New York University School of Medicine and completed his training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, where he served as Clinical Director of the Lank Center for Genitourinary Oncology.
Dr. Oh will continue to care for his patients as Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, where he has been recognized by New York Magazine as a Best Doctor for the past decade.
“I am very excited to join Sema4, a company which I believe is at the forefront of a healthcare revolution in precision medicine and use of data to help patients optimize their health,” said Dr. Oh. “As an oncologist, I recognize the challenge of optimizing a patient’s journey—from assessing the risk of cancer to determining treatment options to monitoring in remission—with more information than busy clinicians can process. Sema4 has a world-class multidisciplinary team building innovative tools to help patients and their physicians make the best healthcare decisions possible with genomics, clinical data, and deep analytics to live their best lives.”
Disclosure: Icahn School of Medicine at Mount Sinai (ISMMS) owns equity in Sema4, and Drs. Schadt and Oh are part-time employees and faculty of ISMMS and have a financial interest in Sema4.
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.